Header graphic for print
LimeGreenIP News

Tag Archives: CFDA

Major IP reforms foreshadowed in China’s Pharma sector.

On 12 May 2017, the Chinese Food and Drug Administration (the “CFDA”) issued several draft policies aimed at overhauling of the current regulations governing the Chinese pharma and medical device sector (the “Draft Policies”). Amongst the Draft Policies, those outlined in Circular No.55 would, if implemented, establish a more robust patent linkage system, a more

China: CFDA’s First Circular in 2015 Opens a Route of Evidence Collection for IP Cases Involving Pharmaceutical Products

Anyone with experience in China knows that, due to lack of discovery, the challenge of obtaining evidence can be a significant deterrence to bringing patent infringement and anti-counterfeiting lawsuits in China.  The recently-promulgated Circular on Issues Relating to Comprehensive Implementation of Electronic Supervision and Administration for Drug Production and Distribution Enterprises (the “Circular“) may give